Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Test Rapidly Identifies Platelet Function Defects

By LabMedica International staff writers
Posted on 06 Aug 2014
A multisurface and multiparameter flow assay to characterize thrombus formation in whole blood from healthy subjects and patients with platelet function deficiencies has been created. More...


Parallel-plate flow chambers have been used for the last two decades to measure platelet adhesion and activation under arterial or venous flow conditions, in particular using surfaces such as extracellular matrix or collagen, but there is a need for further standardization of devices, protocols and measurement parameters.

A team of scientists led by those at Maastricht University (The Netherlands) obtained blood samples from healthy donors and patients who all had a well-defined platelet deficiency and mild bleeding tendency. Microspot-coated coverslips were mounted onto a transparent parallel-plate flow chamber (50 μm depth, 3 mm width and 20 mm length), and pre-rinsed. Anticoagulated whole-blood samples were perfused through the flow chamber for a time period sufficient for full-thrombus formation on collagen I spots and adherence labeled with a fluorescence marker.

A systematic comparison is made of 52 adhesive surfaces with components activating the main platelet-adhesive receptors, and of eight output parameters reflecting distinct stages of thrombus formation. Three types of thrombus formation can be identified with a predicted hierarchy of the following receptors: glycoprotein (GP) VI, C-type lectin-like receptor-2 (CLEC-2) > GPIb > α6β1 αIIbβ3 > α2β1 > CD36, α5β1, αvβ3. Application with patient blood reveals distinct abnormalities in thrombus formation in patients with severe combined immune deficiency, Glanzmann’s thrombasthenia, Hermansky–Pudlak syndrome, May–Hegglin anomaly or grey platelet syndrome. This test may be useful for the diagnosis of patients with suspected bleeding disorders or a pro-thrombotic tendency.

Johan W.M. Heemskerk, PhD, a professor and a senior author of the study said, “To develop this test we collected information on thrombosis formation in a flow chamber with flowing blood. This has never been done before on such a large scale. We can easily determine what’s wrong with the patient by counting the number of platelets in a few drops of blood. If there’s an active bleed, the platelets trigger the coagulation process to stem the bleeding. The opposite is true with thrombosis: in that case, the platelets are overactive and could cause a stroke or a heart attack.” The study was published on July 16, 2014, in the journal Nature Communications.

Related Links:

Maastricht University



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.